Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent

Chang, Lee Hsin; Chuang, Er Yuan; Cheng, Tsai Mu; Lin, Chi; Shih, Chün Ming; Wu, Alexander T.H.; Jheng, Pei Ru; Lu, Hsin Ying; Shih, Chun Che; Mi, Fwu Long

doi:10.1016/j.actbio.2021.07.072

Cited by 35 publications

(30 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This once again leads to diagnostic/therapeutic dose discrepancies, though reversed compared to US imaging. Chang et al showed this, where their theranostic system required concentrations far above the therapeutically relevant dosage to be visible in CT imaging 47 . This may cause toxicity issues, and can result in prohibitive costs associated with such a large dosage, indicating why few theranostic systems are designed for use with CT.…”

Section: Imaging Of Theranostic Nanoparticlesmentioning

confidence: 98%

“…Due to its ability to quickly obtain high-quality images with a high depth of penetration, CT is frequently used for severe acute embolisms requiring rapid diagnosis. Therefore, Chang et al developed a gold nanorod (AuNR) theranostic system which displayed CT contrast capabilities alongside antithrombotic efficacy 47 . However, the use of this system, and the use of CT for diagnosis of thrombosis in general, suffers from some major limitations.…”

Section: Imaging Of Theranostic Nanoparticlesmentioning

confidence: 99%

“…Alternatively, stimulating heating of the nanoparticle itself, rather than its environment, has also been investigated to increase specificity. Chang et al applied this concept in their theranostic nanoparticles, where urokinase containing gold nanorods (AuNRs) could be heated upon stimulation with near-infrared (NIR) light 47 . This facilitated enhanced clot lysis by stimulating localised hyperthermia 47 .…”

Section: Responsive Theranostic Nanocarriersmentioning

confidence: 99%

“…Chang et al applied this concept in their theranostic nanoparticles, where urokinase containing gold nanorods (AuNRs) could be heated upon stimulation with near-infrared (NIR) light 47 . This facilitated enhanced clot lysis by stimulating localised hyperthermia 47 . However, this theranostic system did not contain any heat-responsive materials, thus the urokinase release was non-specific and relatively unresponsive.…”

Section: Responsive Theranostic Nanocarriersmentioning

confidence: 99%

“…Fucoidan is a promising alternative ligand with a high affinity to platelets and has recently been incorporated in a theranostic nanoparticle ( Figure 7 A ) 47 . Fucoidan is an anticoagulant derived from algae, which has also seen use as a P-selectin targeting ligand in several drug delivery systems 107 , 119 and an imaging probe 120 .…”

Section: Opportunities For Targeted Theranostic Systemsmentioning

confidence: 99%

See 4 more Smart Citations

Theranostic nanoparticles for the management of thrombosis

Russell¹,

Hagemeyer²,

Esser³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Acute thrombosis and thromboembolisms are one of the leading causes of mortality and morbidity in both developed and developing countries, placing a huge burden on health and economic systems. Early diagnosis is critical but currently limited in accuracy and hampered by a narrow time frame, where the short therapeutic window also severely restricts treatment options. Additionally, clinically used antithrombotics and thrombolytics suffer from severe side effects and are limited in efficacy by a short half-life and susceptibility to degradation. The use of systems containing both diagnostic and therapeutic moieties, known as theranostics, can potentially improve patient outcomes by increasing the precision and efficacy of diagnosis and treatment, enabling personalised and precision medicine. Leveraging nanomedicine may further improve treatment by improving the system's pharmacokinetic properties including controlled drug delivery. This review provides an overview of the development of such theranostic nanoparticle systems, with a focus on approaches that may be utilised to usher this field towards clinical use.

show abstract

Section: Imaging Of Theranostic Nanoparticlesmentioning

confidence: 98%

Section: Imaging Of Theranostic Nanoparticlesmentioning

confidence: 99%

Section: Responsive Theranostic Nanocarriersmentioning

confidence: 99%

Section: Responsive Theranostic Nanocarriersmentioning

confidence: 99%

Section: Opportunities For Targeted Theranostic Systemsmentioning

confidence: 99%

See 3 more Smart Citations

Theranostic nanoparticles for the management of thrombosis

Russell¹,

Hagemeyer²,

Esser³

et al. 2022

Theranostics

View full text Add to dashboard Cite

show abstract

Plasma‐Derived Nanoclusters for Site‐Specific Multimodality Photo/Magnetic Thrombus Theranostics

Liu,

Jheng

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Traditional thrombolytic therapeutics for vascular blockage are affected by their limited penetration into thrombi, associated off‐target side effects, and low bioavailability, leading to insufficient thrombolytic efficacy. It is hypothesized that these limitations can be overcome by the precisely controlled and targeted delivery of thrombolytic therapeutics. A theranostic platform is developed that is biocompatible, fluorescent, magnetic, and well‐characterized, with multiple targeting modes. This multimodal theranostic system can be remotely visualized and magnetically guided toward thrombi, noninvasively irradiated by near‐infrared (NIR) phototherapies, and remotely activated by actuated magnets for additional mechanical therapy. Magnetic guidance can also improve the penetration of nanomedicines into thrombi. In a mouse model of thrombosis, the thrombosis residues are reduced by ≈80% and with no risk of side effects or of secondary embolization. This strategy not only enables the progression of thrombolysis but also accelerates the lysis rate, thereby facilitating its prospective use in time‐critical thrombolytic treatment.

show abstract

Targeting Nanomotor with Near‐Infrared/Ultrasound Triggered‐Transformation for Polystage‐Propelled Cascade Thrombolysis and Multimodal Imaging Diagnosis

Ruan,

Chen,

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Nowadays, cardiovascular and cerebrovascular diseases caused by venous thromboembolism become main causes of mortality around the world. The current thrombolytic strategies in clinics are confined primarily due to poor penetration of nanoplatforms, limited thrombolytic efficiency, and extremely‐low imaging accuracy. Herein, a novel nanomotor (NM) is engineered by combining iron oxide/perfluorohexane (PFH)/urokinase (UK) into liposome nanovesicle, which exhibits near‐infrared/ultrasound (NIR/US) triggered transformation, achieves non‐invasive vein thrombolysis, and realizes multimodal imaging diagnosis altogether. Interestingly, a three‐step propelled cascade thrombolytic therapy is revealed from such intelligent NM. First, the NM is effectively herded at the thrombus site under guidance of a magnetic field. Afterwards, stimulations of NIR/US propel phase transition of PFH, which intensifies penetration of the NM toward deep thrombus dependent on cavitation effect. Ultimately, UK is released from the collapsed NM and achieves pharmaceutical thrombolysis in a synergistic way. After an intravenous injection of NM in vivo, the whole thrombolytic process is monitored in real‐time through multimodal photoacoustic, ultrasonic, and color Doppler ultrasonic imagings. Overall, such advanced nanoplatform provides a brand‐new strategy for time‐critical vein thrombolytic therapy through efficient thrombolysis and multimodal imaging diagnosis.

show abstract

Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent

Cited by 35 publications

References 54 publications

Theranostic nanoparticles for the management of thrombosis

Theranostic nanoparticles for the management of thrombosis

Plasma‐Derived Nanoclusters for Site‐Specific Multimodality Photo/Magnetic Thrombus Theranostics

Targeting Nanomotor with Near‐Infrared/Ultrasound Triggered‐Transformation for Polystage‐Propelled Cascade Thrombolysis and Multimodal Imaging Diagnosis

Contact Info

Product

Resources

About